{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:47:27Z","timestamp":1785901647449,"version":"3.56.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.bmcl.2019.126944","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T11:43:19Z","timestamp":1577965399000},"page":"126944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Development of novel NLRP3-XOD dual inhibitors for the treatment of gout"],"prefix":"10.1016","volume":"30","author":[{"given":"Weiwei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hee","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengze","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhubin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1487-6893","authenticated-orcid":false,"given":"Huanqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2019.126944_b0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13075-015-0609-2","article-title":"An update on the genetic architecture of hyperuricemia and gout","volume":"17","author":"Merriman","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bmcl.2019.126944_b0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/BOR.0000000000000366","article-title":"Factors modulating the inflammatory response in acute gouty arthritis","volume":"29","author":"Cleophas","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.bmcl.2019.126944_b0015","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.bbrc.2018.02.166","article-title":"Serum levels of IL-17 are elevated in patients with acute gouty arthritis","volume":"497","author":"Liu","year":"2018","journal-title":"Biochem Bioph Res Co"},{"key":"10.1016\/j.bmcl.2019.126944_b0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185704","article-title":"The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice","volume":"12","author":"Reber","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmcl.2019.126944_b0025","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/1440-1681.12647","article-title":"Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity suppresses microglia-mediated inflammatory responses","volume":"43","author":"Zhang","year":"2016","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.bmcl.2019.126944_b0030","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/cns.13116","article-title":"Mitochondrial dysfunction in neurodegenerative diseases and the potential countermeasure","volume":"25","author":"Wan","year":"2019","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.bmcl.2019.126944_b0035","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1759720X16646703","article-title":"Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications","volume":"8","author":"Sattui","year":"2016","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.bmcl.2019.126944_b0040","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2217\/pgs.15.21","article-title":"Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review","volume":"16","author":"Jarjour","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bmcl.2019.126944_b0045","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrrheum.2017.126","article-title":"Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)","volume":"13","author":"Dalbeth","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bmcl.2019.126944_b0050","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3899\/jrheum.151476","article-title":"Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions","volume":"44","author":"Ke","year":"2017","journal-title":"J rheumatol"},{"key":"10.1016\/j.bmcl.2019.126944_b0055","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jare.2017.05.001","article-title":"Asymptomatic hyperuricemia and chronic kidney disease: narrative review of a treatment controversial","volume":"8","author":"Eleftheriadis","year":"2017","journal-title":"J Adv Res"},{"key":"10.1016\/j.bmcl.2019.126944_b0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-115-3-165","article-title":"Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease","volume":"115","author":"Sandler","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bmcl.2019.126944_b0065","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/BOR.0000000000000143","article-title":"Interleukin-1 as a therapeutic target in gout","volume":"23","author":"Dumusc","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.bmcl.2019.126944_b0070","doi-asserted-by":"crossref","first-page":"16410","DOI":"10.4238\/2015.December.9.10","article-title":"Investigation on the association between NLRP3 gene polymorphisms and susceptibility to primary gout","volume":"14","author":"Wang","year":"2015","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.bmcl.2019.126944_b0075","doi-asserted-by":"crossref","first-page":"64845","DOI":"10.1371\/journal.pone.0064845","article-title":"Association of TLR4 Gene rs2149356 polymorphism with primary gouty arthritis in a case-control study","volume":"8","author":"Qing","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmcl.2019.126944_b0080","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.1184003","article-title":"The NLRP3 inflammasome: a sensor for metabolic danger?","volume":"327","author":"Schroder","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2019.126944_b0085","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ni.1636","article-title":"The NALP3 inflammasome is involved in the innate immune response to amyloid-beta","volume":"9","author":"Halle","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bmcl.2019.126944_b0090","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activated the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2019.126944_b0095","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/BOR.0000000000000146","article-title":"New medications in development for the treatment of hyperuricemia of gout","volume":"27","author":"Diaz-Torn\u00e9","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.bmcl.2019.126944_b0100","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.bmcl.2019.126944_b0105","unstructured":"Huang J, Zhou ZH, Zhou MZ, Miao MX, Li HQ, Hu QH. Development of benzoxazole deoxybenzoin oxime and acyloxylamine derivatives targeting innate immune sensors and xanthine oxidase for treatment of gout. Bioorgan Med."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19309308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19309308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:32:48Z","timestamp":1760772768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X19309308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0960894X19309308"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.126944","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of novel NLRP3-XOD dual inhibitors for the treatment of gout","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.126944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"126944"}}